Craigavon Cardiac Centre, SHSCT, Craigavon, Northern Ireland, UK.
Adv Ther. 2019 Jul;36(7):1549-1573. doi: 10.1007/s12325-019-00962-1. Epub 2019 May 7.
Many important clinical trials in cardiology were published or presented at major international meetings throughout 2018. This paper aims to offer a concise overview of these significant advances and to put them into clinical context.
Trials presented at the major international cardiology meetings during 2018 were reviewed including The American College of Cardiology, EuroPCR, The European Society of Cardiology, PCR London Valves, Transcatheter Cardiovascular Therapeutics, and the American Heart Association. In addition to this a literature search identified several other publications eligible for inclusion based on their relevance to clinical cardiology, their potential impact on clinical practice and on future guidelines.
A total of 78 trials met the inclusion criteria. New interventional and structural data include trials examining novel stent designs (Biofreedom™, COMBO), use of drug-coated balloons in patients with high bleeding risk, intervention in stable coronary artery disease, revascularisation strategy in ST elevation myocardial infarction, transcatheter aortic valve replacement in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included the use of sodium glucose cotransporter-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (alirocumab) and approaches of hypertension management. Antiplatelet data included trials evaluating both the optimal length of course and combination of antiplatelet agents. Heart failure data included trials of sacubitril-valsartan during acute hospital admission and the management of chemotherapy-induced cardiotoxicity. Electrophysiology data included trials examining atrial fibrillation ablation, wearable cardiac defibrillators (LifeVest) and His-bundle pacing.
This article presents key clinical trials completed during 2018 and should be valuable to both cardiology clinicians and researchers.
2018 年，许多重要的心脏病学临床试验在各大国际会议上发表或公布。本文旨在简要概述这些重要进展，并将其纳入临床背景。
本文回顾了 2018 年在主要国际心脏病学会议上公布的试验，包括美国心脏病学会、欧洲经皮心血管介入学会、欧洲心脏病学会、伦敦瓣膜 PCR、经导管心血管治疗、美国心脏协会。此外，通过文献检索，根据与临床心脏病学的相关性、对临床实践的潜在影响以及未来指南，确定了其他一些符合纳入标准的出版物。
共有 78 项试验符合纳入标准。新的介入和结构性数据包括评估新型支架设计（BiofreedomTM，COMBO）的试验、在高出血风险患者中使用药物涂层球囊、稳定型冠状动脉疾病的介入治疗、ST 段抬高型心肌梗死的血运重建策略、低危患者的经导管主动脉瓣置换术，以及经皮二尖瓣或三尖瓣介入治疗。预防心脏病学数据包括钠葡萄糖协同转运蛋白-2 抑制剂（恩格列净、达格列净、卡格列净）、前蛋白转化酶枯草溶菌素 kexin 9（PCSK9）抑制剂（阿利西尤单抗）和高血压管理方法的应用。抗血小板数据包括评估抗血小板药物最佳疗程和联合应用的试验。心力衰竭数据包括在急性住院期间使用沙库巴曲缬沙坦和化疗诱导性心脏毒性管理的试验。电生理学数据包括评估心房颤动消融、可穿戴心脏除颤器（LifeVest）和希氏束起搏的试验。
本文介绍了 2018 年完成的关键临床试验，对心脏病学临床医生和研究人员都有价值。
